Cleared Traditional

K112550 - CAPILLARYS HEMOGLOBIN, CAPILLARYS FLEX PIERCING SYSTEM

K112550 is an FDA 510(k) clearance for CAPILLARYS HEMOGLOBIN, manufactured by Sebia. The device is a Class 2 Hematology device with product code GKA cleared through the Traditional 510(k) pathway after a 267-day FDA review.

K112550 · Sebia · Hematology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
May 2012
Decision
267d
Days
Class 2
Risk

K112550 is an FDA 510(k) clearance for the CAPILLARYS HEMOGLOBIN, CAPILLARYS FLEX PIERCING SYSTEM. Classified as Abnormal Hemoglobin Quantitation (product code GKA), Class II - Special Controls.

Submitted by Sebia (Norcross, US). The FDA issued a Cleared decision on May 25, 2012 after a review of 267 days - an extended review cycle.

This device falls under the Hematology FDA review panel, regulated under 21 CFR 864.7415 - the FDA hematology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Hematology review framework, consistent with the majority of Class II 510(k) submissions.

View all Sebia devices

FDA 510(k) Submission Details - K112550

510(k) Number K112550 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 01, 2011
Decision Date May 25, 2012
Days to Decision 267 days
Submission Type Traditional
Review Panel Hematology (HE)
Summary Statement
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
154d slower than avg
Panel avg: 113d · This submission: 267d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

GKA Device Classification - Class 2, Special Controls

Product Code GKA Abnormal Hemoglobin Quantitation
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 864.7415
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Hematology devices follow this clearance model.

Regulatory Peers - GKA Abnormal Hemoglobin Quantitation

All 20
Devices cleared under the same product code (GKA) and FDA review panel - the closest regulatory comparables to K112550.
V8 Nexus Hemoglobin Ultrascreen, V8 AFSA2 Hemo Control
K192931 · Helena Laboratories, Corp. · Apr 2022
CAPI 3 HEMOGLOBIN(E)
K180762 · Sebia · Dec 2018
Hemoglobin Variants System on Newborn Hemoglobin System with GDM and HbReview Software
K171664 · Bio-Rad Laboratories, Inc. · Sep 2017
SEBIA CAPILLARYS HEMOGLOBIN(E) WITH CAPILLARYS 2
K112491 · Sebia · May 2012
CAPILLARYS NEONAT HB (PN 2006)
K091283 · Sebia · Feb 2010
MINICAP HEMOGLOBIN(E) KIT, MODEL 2207, 2227
K082227 · Sebia · Mar 2009